Latest Issue
Get instant access to latest e-book

LATEST NEWSRead more...

06

Dec 2019

MaxCyte and KSQ Therapeutics Announce Development and Commercialization Agreement to Enable the Advancement of KSQ's Adoptive Cell Therapy Programs

MaxCyte the global cellbased therapies and life sciences company and KSQ Therapeutics a biotechnology company using its proprietary CRISPRomics discovery platform to achieve higher probabilities of success in drug development announced today that the companies have entered into a new development and...

06

Dec 2019

Zionexa Has Signed an Exclusive Agreement With PETNET Solutions Inc. for Manufacturing and Distribution

Zionexa a radiopharmaceutical company specialized in the development and commercialization of invivo biomarkers for use in guiding targeted therapies in oncology and PETNET Solutions Inc a Siemens Healthineers company specializing in the manufacturing and distribution of positron emission tomography...

05

Dec 2019

Gatehouse Bio collaborates with AstraZeneca to accelerate new drug discovery

Gatehouse Bio a pioneer in nextgeneration therapeutics is collaborating with AstraZeneca a global scienceled biopharmaceutical company to explore the identification of new targets for respiratory and cardiovascular diseases using Gatehouse Bios Artificial Intelligence AIpowered platform

05

Dec 2019

LEO Pharma and Portal Instruments Announce Collaboration to Develop Needle-Free Drug Delivery Device

LEO Pharma AS and Portal Instruments today announced a global collaboration and license agreement to develop Portals innovative needlefree drug delivery system for use in combination with LEO Pharmas portfolio of investigational and approved medicines

04

Dec 2019

RAPT Therapeutics and Hanmi Pharmaceutical Announce Collaboration to Develop and Commercialize FLX475 in Asia

RAPT Therapeutics Inc a clinicalstage immunologybased biopharmaceutical company focused on discovering developing and commercializing oral small molecule therapies for patients with significant unmet needs in oncology and inflammatory diseases and Hanmi Pharmaceutical Co LTD today announced a licens...

04

Dec 2019

Resonant Therapeutics Announces Collaboration with Janssen

Resonant Therapeutics Inc announced that the company has entered into an agreement with Janssen Research and Development LLC Janssen with the aim to discover and validate novel tumor and immunological targets and to validate certain therapeutic candidates

03

Dec 2019

Neurocrine Biosciences and Xenon Pharmaceuticals Announce Agreement to Develop First-in-Class Treatments for Epilepsy

Neurocrine Biosciences Inc and Xenon Pharmaceuticals Inc announced a license and collaboration agreement to develop firstinclass treatments for epilepsyNeurocrine Biosciences gains an exclusive license to XEN a clinical stage selective Nav sodium channel inhibitor with potential in SCNA developmenta...

03

Dec 2019

Astellas Enters into Definitive Agreement to Acquire Audentes Therapeutics

Astellas Pharma Inc and Audentes Therapeutics Inc today announced that they have entered into a definitive agreement for Astellas to acquire Audentes at a price of US per share in cash representing a total equity value of approximately US billionRecent scientific and technological advances in geneti...

02

Dec 2019

Innovent Biologics Announces FDA Acceptance of NDA for Pemigatinib in Patients

Innovent Biologics Inc Innovent or the Company HKEX a worldclass biopharmaceutical company that develops and commercializes high quality medicines for the treatment of oncology autoimmune metabolic and other major diseases today announced that the new drug application NDA submitted by Incyte to the...

press releasesRead more...

06

Dec 2019

MedPharm, the leader in topical and transdermal drug delivery, has moved into its newly expanded facility in Durham, North Carolina

The M expansion has tripled the facilitys footprint to approximately sq ft significantly expanding capacity and supporting MedPharms continued commitment to the topical and transdermal market

06

Dec 2019

Galectin Therapeutics Plans Adaptively Designed Phase 3 NASH-RX Clinical Trial in NASH Cirrhosis

Galectin Therapeutics Inc the leading developer of therapeutics that target galectin proteins recently presented its current plans for an Adaptively Designed Phase clinical trial NASHRX of its lead compound belapectin GRMD in the treatment of patients with nonalcoholic steatohepatitis NASH cirrhosi...

06

Dec 2019

Alector Announces FDA Fast Track Designation Granted to AL001 for the Treatment of Patients with Frontotemporal Dementia

Alector Inc a clinical stage biotechnology company pioneering immunoneurology today announced that the US Food and Drug Administration FDA has granted Fast Track designation for its investigational therapeutic AL for the treatment of patients with frontotemporal dementia FTD carrying specific geneti...

05

Dec 2019

Schreiner MediPharm and PragmatIC Announce Strategic Partnership for Smart Pharma Labels

Schreiner MediPharm a specialist in innovative functional labels for the pharmaceutical industry and PragmatIC a world leader in low cost flexible electronics have entered into a strategic partnership The purpose of the cooperation is to offer manufacturers of pharmaceutical products and medical dev...

05

Dec 2019

Eisai to Present Latest Data on Alzheimer's Disease / Dementia Pipeline at 12th Clinical Trials on Alzheimer's Disease Conference

Eisai Co Ltd announced today that three oral presentations and eight poster presentations highlighting the latest data on its Alzheimers disease dementia pipeline including antiamyloid beta Abeta protofibril antibody BAN orexin receptor antagonist lemborexant and a simple blood diagnostic for Alzhe...

05

Dec 2019

Emergency Medicine Conference to kick off in Abu Dhabi this week

The Emirates Society of Emergency Medicine Conference ESEM is going to be held from th to Th of December at the Jumeirah At Etihad Towers in Abu Dhabi United Arab Emirates ESEM conference is the largest ongoing annual gathering on emergency medicine in the middle east primarily in the areas of Pre...

05

Dec 2019

Tetra Bio-Pharma Receives FDA Orphan Drug Designation for Hepatocellular Carcinoma

Tetra BioPharma Inc a leader in cannabinoidderived drug discovery and development today announced it has received US Food and Drug Administration FDA Orphan Drug Designation for deltatetrahydrocannabinol THC in the treatment of hepatocellular carcinoma

05

Dec 2019

Adastra Pharmaceuticals Announces FDA and EMA Orphan Drug Designation Has Been Granted for Zotiraciclib in the Treatment of Glioma

Adastra Pharmaceuticals Inc a biopharmaceutical company focused on the development of firstinclass therapeutics for the treatment of cancer today announced that the US Food and Drug Administration FDA and the European Medicines Agency EMA have granted Orphan Drug Designation to zotiraciclib for the...

04

Dec 2019

Piramal Pharma Solutions Announces Collaboration With BerGenBio on the Development of FDA Fast Track Designated Leukemia Treatment

Piramal Enterprises Limiteds Pharma Solutions business a leading Contract Development and Manufacturing Organization CDMO today announced that the company will be partnering with BerGenBio ASA OSE BGBIO on the development of bemcentinib for the treatment of elderly patients with relapsed Acute Myelo...

EventsRead more...

09 - 10

Dec 2019

Pharmacy and Pharmaceutical Conference

https://pharma.pharmaceuticalconferences.com/
Dubai

09 - 13

Dec 2019

Antibody Engineering And Therapeutics

Knect365
Marriott Marquis San Diego

09 - 13

Dec 2019

09 - 10

Dec 2019

Pharmacology and Toxicology

Me Conferences
Dubai, UAE

10 - 12

Dec 2019

Gene Therapy for Neurological Disorders

Hanson Wade
The Colonnade Hotel

11 - 13

Dec 2019

Drug Delivery to the Lungs 2019

Edinburgh International Conference Centre

11 - 12

Dec 2019

12 - 13

Dec 2019

14th Biosimilars Congregation 2019

Kohinoor Continental Hotel

Advertisements

TOP ARTICLES

KNOWLEDGE BANK

  • Interviews

    Merck

    Staff Engineer, Manufacturing Science and Technology, South East Asia

    Karen Chan is a process engineer at Merck Pte Ltd Chan has six years of experience in the biopharmaceutical industry and two years of experience in research development She provides technical support in areas such as process development troubleshoot...
  • Articles

    A Concise Treatise on Hard and Soft Nanomaterials for Drug Delivery

    Most of the conventional free drugs suffer from high side effects poor adsorption poor solubility high drug dosing minimum efficiency uncontrolled and nonspecific delivery with high cytotoxicity which limit their uses With respect to the chemotherapeutic drugs concern is more because most of the anticancer drugs are highly toxic for the healthy cells and damage the he...

EDITORIAL SECTION

  • STRATEGY

    REDUCTION OF HEALTH COSTS

    Since autumn the first package of costcutting measures in Switzerlands healthcare system is being reviewed One of the measures is the socalled refere...